A trial looking at tivantinib with erlotinib for non small cell lung cancer that has spread (MARQUEE)
Cancer type:
Status:
Phase:
This trial looked at tivantinib and erlotinib for non small cell lung cancer that had got worse despite other treatment. It was for people with non squamous cell cancer, such as 
or .
The trial was open for people to join between 2011 and 2012. The team published the results in 2015.
More about this trial
Doctors may treat advanced non small cell lung cancer (NSCLC) with targeted treatments called called tyrosine kinase inhibitors (TKIs). They block signals which cancer cells need to divide and grow.
When this trial was done, doctors were already using erlotinib to treat advanced lung cancer. They wanted to find out if having tivantinib (ARQ 197) as well would be useful.
Tivantinib is also a TKI, but it works in a different way to erlotinib.
The people taking part were put into a treatment group at random:
- half had erlotinib and tivantinib
- half had erlotinib and a dummy drug (placebo)
The main aim of this trial was to see if erlotinib and tivantinib helps people with advanced NSCLC more than erlotinib alone.
Summary of results
As part of our editorial policy, any trial information we write is checked externally before we put it on our website. The research team have published some results for this trial. But we have been unable to find anyone involved with the trial to check the summary for us.
This means we are not able to include a plain English summary of the results on this page.
More information
There is more information about this trial in the link to the medical journal below.
Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer
G Scagliotti and others
Journal of Clinical Oncology, 2015. Volume 33, issue 24, pages 2667 – 2676.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr Conrad Lewanski
Supported by
ArQule Inc
Daiichi Sankyo
Experimental Cancer Medicine Centre (ECMC)
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
